Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This protocol outlines a randomized,open label trial examining the safety, pharmacology and
efficacy of Glucagon like peptide 2 (GLP-2) in infants and children with intestinal failure.
The investigators hypothesize that GLP-2 given subcutaneously in these patients will be well
tolerated, and have similar metabolism to what has been shown in adults. The investigators
also expect to show an improvement in the tolerance of enteral nutrition, and a decreased
requirement for intravenous feeding.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alberta Children's Hospital
Collaborators:
British Columbia Children's Hospital Stollery Children's Hospital The Hospital for Sick Children